Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced the FDA approval and U.S. launch of a generic version of Saxenda. “With this approval, and by launching a generic for Saxenda, we will provide patients in the U.S. the first ever generic GLP-1 product specifically indicated for weight loss,” said Ernie Richardsen, SVP, Head of U.S. Commercial Generics at Teva. “This is the fifth first-to-market entry of a Teva generic this year and is an important addition to Teva’s diverse complex generics portfolio, demonstrating once again our proven ability to sustain a world class Generics Powerhouse.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Acadia Pharmaceuticals names Katcheves Chief Business and Strategy Officer
- Teva put volume heavy and directionally bearish
- GS, BAC, LEN: Billionaire Investor Stanley Druckenmiller Buys Bank and Housing Stocks
- Teva announces U.S. FDA has approved AJOVY for preventive treatment
- Teva Pharmaceuticals Reports Improved Earnings Amid Strategic Focus